| Literature DB >> 36248968 |
Weicui Chen1, Yongsong Ye1, Daochun Zhang2, Liting Mao1, Lei Guo1, Hanliang Zhang1, Xiaohua Du3, Weiwei Deng4, Bo Liu1, Xian Liu1.
Abstract
Objectives: To assess the utility of Dual-layer spectral-detector CT (DLCT) in predicting the pT stage and histologic grade for colorectal adenocarcinoma (CRAC).Entities:
Keywords: X-ray computed; colorectal neoplasms; neoplasm staging; pathology; tomography
Year: 2022 PMID: 36248968 PMCID: PMC9564703 DOI: 10.3389/fonc.2022.1002592
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 5.738
Figure 1Flowchart of patient selection. CRAC, colorectal adenocarcinoma; DLCT, dual-layer spectral-detector CT.
Clinical pathological characteristics on 131 CRAC.
| Variables | All patients | pT Stages |
| Histologic Grade |
| |||
|---|---|---|---|---|---|---|---|---|
| pT1-2 | pT3 | pT4 | High | Low | ||||
| No. of patients | 131 | 35 | 61 | 35 | 32 | 99 | ||
| Age (years), mean ± SD | 62.7 ± 12.9 | 61.7 ± 10.4 | 61.7 ± 14.0 | 65.2 ± 130 | 0.388 | 60.6 ± 11.7 | 63.3 ± 13.2 | 0.306 |
| Gender, No. (%) | 0.758 | 0.061 | ||||||
| Female | 55.0 (72/131) | 51.4 (18/35) | 54.1 (33/61) | 60.0 (21/35) | 40.6 (13/32) | 59.6 (59/99) | ||
| Male | 45.0 (59/131) | 48.6 (17/35) | 45.9 (28/61) | 40.0 (14/35) | 59.4 (19/32) | 40.4 (40/99) | ||
| CA19-9 level, No. (%) | <0.001 | 0.078 | ||||||
| Normal | 45.0(59/131) | 80.0 (28/35) | 32.8 (20/61) | 31.4 (11/35) | 25.0 (8/32) | 42.4 (42/99) | ||
| Abnormal | 55.0 (72/131) | 20.0 (7/35) | 67.2 (41/61) | 68.6 (24/35) | 75.0 (24/32) | 57.6 (57/99) | ||
| CEA level, No. (%) | <0.001 | 0.467 | ||||||
| Normal | 42.0 (55/131) | 88.6 (31/35) | 29.51 (18/61) | 17.1 (6/35) | 31.3 (10/32) | 38.4 (38/99) | ||
| Abnormal | 58.0 (76/131) | 11.4 (4/35) | 70.5 (43/61) | 82.9 (29/35) | 68.8 (22/32) | 61.6 (61/99) | ||
| Tumor location, No. (%) | 0.037 | 0.247 | ||||||
| Right colon | 21.4 (28/131) | 14.3 (5/35) | 19.7 (12/61) | 31.4 (11/35) | 25.0 (8/32) | 20.2 (20/99) | ||
| Left colon | 41.2 (54/131) | 28.6 (10/35) | 45.9 (28/61) | 45.7 (16/35) | 50.0 (16/32) | 38.4 (38/99) | ||
| Rectum | 37.4 (49/131) | 57.1 (20/35) | 34.4 (21/61) | 22.9 (8/35) | 25.0 (8/32) | 41.4 (41/99) | ||
| Upper Rectum | 18.3 (24/131) | 34.3 (12/35) | 13.1 (8/61) | 11.4 (4/35) | 9.4 (3/32) | 20.2 (20/99) | ||
| Middle Rectum | 11.5 (15/131) | 20.0 (7/35) | 11.5 (7/61) | 2.9 (1/35) | 6.3 (2/32) | 18.2 (18/99) | ||
| Low Rectum | 7.6 (10/131) | 8.6 (3/35) | 9.8 (6/61) | 8.6 (3/35) | 9.4 (3/32) | 3.0 (3/99) | ||
| pN stage, No. (%) | 0.001 | <0.001 | ||||||
| pN0 | 49.6 (65/131) | 65.7 (23/35) | 52.5 (32/61) | 28.6 (10/35) | 12.5 (4/32) | 53.5 (53/99) | ||
| pN1 | 25.2 (33/131) | 31.4 (11/35) | 21.3 (13/61) | 25.7 (9/35) | 37.5 (12/32) | 19.2 (19/99) | ||
| pN2 | 25.2 (33/131) | 52.9 (1/35) | 26.2 (16/61) | 45.7 (16/35) | 50.0 (16/32) | 27.3 (27/99) | ||
| pT stage, No. (%) | / | 0.686 | ||||||
| pT1-2 | 26.7 (35/131) | / | / | / | 12.5 (4/32) | 19.2 (19/99) | ||
| pT3 | 46.6 (61/31) | / | / | / | 56.3 (18/32) | 52.5 (52/99) | ||
| pT4 | 26.7 (35/131) | / | / | / | 31.3 (10/32) | 28.3 (28/99) | ||
| Histologic grade, No. (%) | 0.238 | / | ||||||
| High | 24.4 (32/131) | 17.1 (6/35) | 31.2 (19/61) | 20.0 (7/35) | / | / | ||
| Low | 75.6 (99/131) | 82.9 (29/35) | 68.9 (42/61) | 80.0 (28/35) | / | / | ||
CRAC, colorectal adenocarcinoma; pT, pathological tumor; CEA, carcino-embryonicantigen; CA19-9, carbohydrate antigen 19-9; pN, pathological lymph node.
Staging of tumors was in accordance with American Joint Committee on Cancer TNM classification;grading of tumors was based on the WHO grading criteria.
Normally distributed data were analyzed by Student’s t test or ANOVA, and were expressed as means ± standard deviations.
Intraobserver reliabilty and interobserver agreement of DLCT parameter measurement.
| Parameter | Intraobserver Reliability (ICC, 95%CI) | Interobserver Agreement (ICC, 95%CI) |
|---|---|---|
| Eff-Z | 0.921 (0.885~0.952) | 0.969 (0.937~0.985) |
| AP | ||
| CT40keV (HU) | 0.962 (0.942~0.976) | 0.912 (0.826~0.957) |
| CT100keV (HU) | 0.983 (0.978~0.987) | 0.890 (0.771~0.947) |
| ICtumor (ug/ml) | 0.980 (0.952~0.992) | 0.856 (0.739~0.923) |
| ICartery (ug/ml) | 0.975 (0.937~0.990) | 0.934 (0.876~0.956) |
| VP | ||
| CT40keV (HU) | 0.971 (0.929~0.988) | 0.954 (0.905~0.978) |
| CT100keV (HU) | 0.948 (0.877~0.980) | 0.900 (0.791~0.952) |
| ICtumor (ug/ml) | 0.959 (0.900~0.984) | 0.923 (0.850~0.960) |
| ICartery (ug/ml) | 0.975 (0.947~0.992) | 0.966 (0.934~0.983) |
DLCT, dual-layer spectral-detector CT; ICC, intra-class correlation coefficients; CI, confidence interval; Eff-Z, effective atomic number; AP, arterial phase; IC, iodine concentration; VP, venous phase.
Comparison DLCT parameter values between different pT stages and histologic grades, and the correlations with pT stages.
| Parameter | pT Stages |
|
|
| Histologic Grade |
| |||
|---|---|---|---|---|---|---|---|---|---|
| pT1-2 (n = 35) | pT3 (n = 61) | pT4 (n = 35) | High (n = 32) | Low (n = 99) | |||||
| Eff-Z | 7.21 (0.09) | 7.31 (0.10) | 7.35 (0.19) | <0.001 | 0.503 | <0.001 | 7.37 (0.10) | 7.28 (0.08) | <0.001 |
| NICAP | 0.11 (0.05) | 0.15 (0.08) | 0.15 (0.08) | <0.001 | 0.455 | <0.001 | 0.20 (0.10) | 0.13 (0.08) | <0.001 |
| λHUAP | 1.20 (0.45) | 1.93 (1.18) | 2.37 (0.91) | <0.001 | 0.512 | <0.001 | 2.59 (1.11) | 1.63 (0.75) | <0.001 |
| NICVP | 0.27 (0.06) | 0.34 (0.11) | 0.35 (0.12) | <0.001 | 0.394 | <0.001 | 0.35 (0.07) | 0.31 (0.11) | 0.015 |
| λHUVP | 2.07 (0.68) | 2.35 (0.62) | 3.09 (1.07) | <0.001 | 0.376 | <0.001 | 2.40 (0.82) | 2.35 (0.84) | 0.902 |
DLCT, dual-layer spectral-detector CT; pT, pathological stage; Eff-Z, effective atomic number; NIC, normalized iodine concentration; AP, arterial phase; VP, venous phase; λHU, slope of the spectral HU curve.
Non-normally distributed data were analyzed by Mann-Whitney U test or Kruskal-Wallis H test, and were expressed as medians (interquartile ranges).
Figure 2Box and whisker plots of (A) effective atomic number (Eff-Z) in pre-contrast phase, (B) normalized iodine concentration (NIC) in arterial and venous phase (VP), (C) spectral HU curve (λHU) in arterial and VP of different pathological tumor (pT) stage colorectal adenocarcinoma (CRAC); (D) Eff-Z in pre-contrast phase, (E) NIC in arterial and VP, (F) λHU in arterial and VP of high- and low-grade CRAC. Boxes show the upper and lower quartiles, and horizontal lines within boxes indicate median values. Whiskers represent the 95th and fifth percentiles. High- and low-grade CRAC showed no difference in λHU from VP (P>0.05), whereas differences in the rest of quantitative parameter values were observed between different pT stages and histologic grades (all P<0.05).
Figure 461-year-old man with pathological tumor stage 3 and grade 3 colon adenocarcinoma, who underwent preoperative dual-layer spectral-detector CT. (A) Axial arterial phase (AP) contrast-enhanced image shows an irregular mass of the descending colon. (B) 40 keV virtual mono-energetic image (VMI) in AP shows apparent contrast enhancement between the lesion and surrounding tissue. (C) Iodine map in AP shows the lesion with an iodine concentration (IC) value of 1.13 mg/ml; the external iliac artery at the same slice with an IC value of 5.47 mg/ml; a normalized iodine concentration (NIC) value of lesion was 0.21 in AP. (D) Effective atomic number (Eff-Z) images in the pre-contrast phase shows the colorful lesion with an Eff-Z value of 7.39. (E) Coronal reconstruction 40 keV VMI shows the tumor located in descending colon. (F) H E staining demonstrates the tumor with a minor glandular component (×40). (G) The tumor cells invade beyond the muscularis propria (×40).
Performance of DLCT parameters in differentiating advanced- from early-stage CRAC.
| Parameter | AUC | Cutoff | Sensitivity (%) | Specificity (%) | Youden index J | 95% CI |
|
|---|---|---|---|---|---|---|---|
| Eff-Z | 0.826 | 7.26 | 81.25 | 74.29 | 0.555 | 0.750~0.887 | <0.001 |
| NICAP | 0.803 | 0.10 | 89.58 | 60.00 | 0.496 | 0.724~0.867 | <0.001 |
| λHUAP | 0.859 | 1.50 | 83.33 | 77.14 | 0.605 | 0.787~0.913 | <0.001 |
| NICVP | 0.793 | 0.32 | 60.42 | 85.71 | 0.461 | 0.713~0.859 | <0.001 |
| λHUVP | 0.682 | 2.10 | 75.00 | 54.29 | 0.293 | 0.595~0.760 | <0.001 |
CRAC, colorectal adenocarcinoma; AUC, area under curve; CI, confidence interval; Eff-Z, effective atomic number; NIC, normalized iodine concentration; AP, arterial phase; VP, venous phase; λHU, slope of the spectral HU curve.
Figure 5Receiver operating characteristic curves for predicting high-grade (A) and advanced-stage and (B) CRAC. Details of the area under the curves of each metric are shown in the results section. CRAC, colorectal adenocarcinoma.
Performance of DLCT parameters in differentiating high- from low-grade CRAC.
| Parameter | AUC | Cutoff | Sensitivity (%) | Specificity (%) | Youden index J | 95% CI |
|
|---|---|---|---|---|---|---|---|
| Eff-Z | 0.812 | 7.31 | 90.62 | 76.77 | 0.674 | 0.735~0.875 | <0.001 |
| NICAP | 0.805 | 0.16 | 68.75 | 74.75 | 0.435 | 0.726~0.869 | <0.001 |
| λHUAP | 0.815 | 1.86 | 93.75 | 64.65 | 0.584 | 0.738~0.877 | <0.001 |
| NICVP | 0.643 | 0.31 | 78.12 | 52.53 | 0.307 | 0.555~0.725 | 0.0067 |
CRAC, colorectal adenocarcinoma; AUC, area under curve; CI, confidence interval; Eff-Z, effective atomic number; NIC, normalized iodine concentration; AP, arterial phase; VP, venous phase; λHU, slope of the spectral HU curve.